Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiloride for lithium-induced chronic nephropathy
NL-OMON20246Recruiting
- Sponsor
- Elisabeth-TweeSteden Ziekenhuis
- Start
- Sep 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of amiloride and lithium in Lithium nephropathy and chronic kidney disease (CKD) (2 arms), sponsored by Elisabeth-TweeSteden Ziekenhuis. Primary endpoint: Change in slope of plasma creatinine concentration. Started Sep 2009; status: recruiting.
02
Drugs
amiloridelithium
03
Conditions
Lithium nephropathychronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON20246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20246.